Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

This study has been completed.
Information provided by (Responsible Party):
Tomoshi Tsuchiya, Nagasaki University Identifier:
First received: October 21, 2011
Last updated: September 23, 2014
Last verified: September 2014
The investigators confirm the feasibility of 1-year administration of oral fluoropyrimidine S-1 as an adjuvant chemotherapy for the patient who received complete resection of non-small cell lung cancer. The investigators presume they can achieve high completion rate with low toxicity.

Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: S-1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Feasibility Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Tomoshi Tsuchiya, Nagasaki University:

Primary Outcome Measures:
  • Completion rate [ Time Frame: One year ]

Secondary Outcome Measures:
  • Incidence and grade of adverse reactions [ Time Frame: One year ]

Estimated Enrollment: 55
Study Start Date: June 2005
Study Completion Date: March 2012
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: S-1
Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
Drug: S-1
Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
Other Name: Oral fluoropyrimidine S-1

Detailed Description:
Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of S-1 (FT, gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 mg/body/day according to body surface area (BSA): BSA <1.25 m2, 80 mg/day; BSA >1.25 m2 but <1.5 m2, 100 mg/day; and BSA >1.5 m2, 120 mg/day. S-1 was administered orally, twice daily after meals, starting within 4 weeks after surgery.

Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. NSCLC with histological proof.
  2. Pathological stage IB, II, or IIIA NSCLC (fifth edition of UICC/AJCC 1997) after complete resection.
  3. No prior treatment except for surgery.
  4. Sufficient oral intake.
  5. Performance status (PS) 0 or 1.
  6. Patients also had to have adequate organ function (3500 <leukocytes < 12,000/mm3; thrombocytes, >100,000/mm3; total bilirubin,<1.5 mg/dl; AST and ALT, less than twice the normal limits at each institution; BUN, <25 mg/dl; creatinine, less than the normal limits at each institution; and creatinine clearance (Ccr))

Exclusion Criteria:

  1. History of drug hypersensitivity.
  2. Contraindication of oral S-1 administration (refer appended paper).
  3. Serious surgical or non-surgical complications
  4. Active secondary cancer.
  5. Watery diarrhea.
  6. Pregnant or lactating women.
  7. Male who has intention to make pregnant
  8. Patient to whom primary doctor judged inadequate to register.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01459185

Division of Surgical Oncology, Nagasaki University Graduate School of BIomedical Sciences
Nagasaki, Japan, 852-8501
Sponsors and Collaborators
Tomoshi Tsuchiya
Study Chair: Takeshi Nagayasu, MD. PhD. Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
  More Information

Responsible Party: Tomoshi Tsuchiya, Senior Assistant Professor, Nagasaki University Identifier: NCT01459185     History of Changes
Other Study ID Numbers: R000007795
Study First Received: October 21, 2011
Last Updated: September 23, 2014

Keywords provided by Tomoshi Tsuchiya, Nagasaki University:
Non-small cell lung cancer
Adjuvant chemotherapy
oral fluoropyrimidine
Feasibility study

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on May 25, 2017